Two Months In: Strong Growth From Nuvation Bio and Caris Life Sciences
For the past two months, I've been invested in Nuvation Bio and Caris Life Sciences. Their stock prices have performed very well.
Moc
před 5 měsíci
NUVB reported preliminary net product revenue of $24.7 million for IBTROZI since launch
Nuvation Bio Inc. (NUVB) reported preliminary net product revenue of $24.7 million for IBTROZI since its launch in June 2025, with fourth quarter revenue reaching $15.7 million.
The company said 432 patients started treatment on IBTROZI for advanced ROS1-positive non-small cell lung cancer since the drug’s launch, with 216 new patients beginning treatment in the fourth quarter. The treatment adoption rate is approximately six times greater than prior ROS1 tyrosine kinase inhibitor launches based on IQVIA data, according to the company.
Nuvation Bio received a $25 million milestone payment from Nippon Kayaku in the fourth quarter following establishment of a reimbursement price in Japan. The company reported preliminary cash, cash equivalents and marketable securities of approximately $529.2 million as of December 31, 2025.
On January 11, 2026, the company entered an exclusive license and collaboration agreement with Eisai Co., Ltd. to develop, register and commercialize taletrectinib for ROS1-positive non-small cell lung cancer in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India.
IBTROZI received FDA approval on June 11, 2025, for treating adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer following Priority Review and Breakthrough Therapy designations.
The company plans to continue enrollment of its phase 3 study evaluating safusidenib in high-grade and high-risk IDH1-mutant gliomas and pursue business development opportunities to expand its pipeline.
The preliminary financial results are subject to adjustment pending completion of the company’s financial closing procedures. Nuvation Bio expects to issue full financial results for the fourth quarter and full year 2025 in March 2026.
Moc
před 7 měsíci
Good news
$NUVB announced the publication of positive Phase 2 study results for safusidenib in treating grade 2 IDH1-mutant glioma patients. The findings were published in the journal Neuro-Oncology on November 8.
The study evaluated 27 patients with IDH1-mutant grade 2 gliomas who had received no prior anticancer therapy except for resection or biopsy. The trial met its primary endpoint with an objective response rate of 44.4%. At 24 months, 87.9% of patients remained progression-free.
Median progression-free survival had not been reached as of the March 10, 2023 data cutoff, with a median follow-up time of 28 months. The median duration of response could not be estimated because no progression events had occurred.
Adverse events were described as mostly mild to moderate. Grade 3 or greater treatment-related adverse events occurred in five patients (18.5%). Three patients discontinued treatment due to adverse events, two of which investigators considered related to safusidenib.
The company noted that a Good Clinical Practice noncompliance issue regarding adverse event collection was identified during the study. Safety data was subsequently re-investigated and re-collected according to study protocol.
Safusidenib is an oral, brain-penetrant inhibitor of mutant IDH1. Nuvation Bio is progressing the ongoing G203 study in high-grade IDH1-mutant gliomas, with a protocol amendment planned to finalize the study as a global Phase 3 trial to support potential regulatory approvals.
The company stated that as of September 15, 2025, 12 patients remained on treatment with safusidenib. Gliomas are the most common type of brain cancer in adults, with nearly 2,400 people diagnosed with IDH1-mutant gliomas annually in the United States.
BailyW
před 7 měsíci
Up?
Has this got anymore juice? Holding nicely. What do people think?
Tato stránka může obsahovat obsah vytvořený komunitou, za který společnost Trading 212 nenese odpovědnost. Vždy prováděj vlastní průzkum. Trading 212 poskytuje pouze exekuční služby a nenabízí investiční poradenství ani správu portfolia.
Tvorba bohatství je zvyk. Automatizuj ho pomocí Pie.
Investuj do předpřipravených pies, nebo si vytvoř své vlastní výběrem z tisíců akcií a ETF
Zjistit více
Zjistit více
Zhlédnout video
Vlastni i ty nejdražší akcie jako Google, Amazon a Apple
Zhlédnout video
Euronext Paris
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
London Stock Exchange
Euronext Lisabon
Euronext Paris
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
London Stock Exchange
Euronext Lisabon
Zobrazit všechny obchodní nástroje
Podpora 24/7
Průměrná doba odezvy 29 sekund
Začni budovat své bohatství teď
Přidej se k více než 5 milionům uživatelů
Získat aplikaci
Otevřít účet
Získej mobilní aplikaci
Všechny prezentované statistiky jsou globální. Počet klientů představuje financované účty.
Skvělé
Hodnoceno 4,6 / 5 založeno na 95 591 hodnoceních
Trustpilot
Hodnoceno 4,6 / 5 založeno na 95 591 hodnoceních
Trustpilot
Pozvaní
Love the Trading 212 App it’s great fun…
Love the Trading 212 App it’s great fun to use and it’s really intuitive in helping you to monitor your investments as they grow!
Pozvaní
Safe,simple and easy
Great website, easy to use. Regular updates. Sit back and do nothing. Couldn’t be simpler. Very happy.
Pozvaní
Great app and easy to use
The Trading 212 app is easy to use and I like the fact you can see your investment grow on a daily basis.
Pozvaní
Very easy account making/saving…
It’s been so easy to create accounts and start investing/saving would recommend to anyone
Pozvaní
Best app
This investment app is very easy to use and has a user-friendly interface. I feel confident knowing my money is secure, and the investment process is simple and straightforward. The customer support is also responsive and helpful whenever needed. Highly recommended for anyone looking for a reliable investment platform!
Pozvaní
Easy and stress free
Investing is made very easy with Trading 212.
Pozvaní
Easy to use
Easy to set up easy to use deposit and take out
Pozvaní
The best trading app out there
The best trading app out there. No question
Pozvaní
Easy to use
Easy to use. I love it
Pozvaní
Low fees ETFs + on of the best interest…
Low fees ETFs + on of the best interest rate on cash attached
Pozvaní
Easy to use
Easy to use, recommend if you’re interested in investing
Pozvaní
Very helpful and professional and my…
Very helpful and professional and my query was dealt with quickly and efficiently.
Pozvaní
All good!
Till now, almost a year after start using it, the experience has been going very well. No issues with any of the activities I needed to perform, friendly user interface and enough tools. I'm also glad that looks like the team ears the community. Keep up the good work.
Pozvaní
A great platform to invest
A great platform to invest. The app is easy to navigate. Easy to transfer money.
Used stocks and shares ISA as well as…
Used stocks and shares ISA as well as Cash ISA.
Like the stocks interface, info about financials of the companies. It does not work very reliably on niche stocks or ETFs, but I would be surprised if it did.
Also it tracks the ISA limits, ISAs are flexible. So can take money in and out all the time. Withdrawals are very quick. They tell it may take few businesses days, but usually goes through in a few minutes (if not seconds).
Cash ISA interest was high, not it is not really, but I suppose it is a price for ability to withdraw anytime.
It would be nice if I could buy government bonds there as stocks and shares ISA product.
Pozvaní
Great experience.
Orders execution is really smooth, level of transparency is amazing when it comes to clear track of transactions and pies is very helpful.
If they just can enable higher freedom when it comes to communication between members in one community/pie, it will be amazing.
Pozvaní
Great app
Great app. Very easy to use. No complications atall
Pozvaní
Great even for beginners
Really easy to use and track investments. Fees are clear and fair.
The ability to communicate with other investors for support is a good feature, especially for beginners.
I'm a newbie to stocks and shares, this app has been perfect to learn with as well as actual investments.
Pozvaní
T212 - The SIPP’er heros.
The Trading 212 team pretty much does all the heavy lifting when setting up a SIPP, you do need to supply the obvious details, and will most likely need to respond to your previous pension provider to confirm your sure with the transfer. But as far as pension pot transfers go, T212 is fantastic! They looked into potential loss of protected terms and brought this up quickly for me to make a decision. The response time from the team is really quick and professional- I cant recommend them enough. I also really like the SIPP interface on the app, its really easy to understand and is seamless with your other investment accounts. 10/10.
Pozvaní
Great site makes investing very easy…
Great site makes investing very easy and exciting, still a little confused on some things but getting there, thanks
Zobrazí se některé z pozitivních recenzí našich klientů
Naše ocenění
Často kladené otázky
Jaká je cena akcie Nuvation Bio (NUVB)?
Aktuální cena Nuvation Bio (NUVB) je 6 $.
Jaké je 52týdenní maximum NUVB?
52týdenní maximum pro NUVB je 9,78 $.
Jaké je 52týdenní minimum NUVB?
52týdenní minimum pro NUVB je 1,78 $.
Jaký je týdenní výkon NUVB?
Za poslední týden se cena NUVB změnila o 17,19 %.
Jaký je měsíční výkon NUVB?
Za poslední měsíc se cena NUVB změnila o 27,12 %.
Jaký je 3měsíční výkon NUVB?
Za poslední tři měsíce se cena NUVB změnila o 42,18 %.
Jaký je 6měsíční výkon NUVB?
Za posledních šest měsíců se cena NUVB změnila o -37,11 %.